EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Soluble Oncoimmunome Signatures Predict Muscle Mass Response to Enriched Immunonutrition in Cancer Patients: Subanalysis of a Multicenter Randomized Clinical Trial

Sara Cuesta-Sancho iD, Juan José López Gomez iD, Pedro Pablo García-Luna iD, David Primo, Antonio J Martínez-Ortega iD, Olatz Izaola, Tamara Casañas, Alicia Calleja, David Bernardo iD, Daniel de Luis iD

Nutrients · 2025

DOI: 10.3390/nu17152421 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Nutrients, 2025. Verfasst von Sara Cuesta-Sancho und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mucosal Immunology Lab, Department of Paediatrics and Immunology, University of Valladolid, 47003 Valladolid, Spain. Hauptthemen laut MEDLINE: Neoplasms, Dietary Supplements, Muscle, Skeletal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Adventia Healthcare SL, Nutrimed Clinical Nutrition.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Enriched oral nutritional supplementation (ONS) has been shown to increase muscle mass in cancer patients. This study aims to identify the immunomodulatory effects and predictive biomarkers associated with this intervention.

Methods

The soluble levels of 92 immune- and oncology-related mediators were determined before and after an intervention (8 weeks) in 28 patients with cancer receiving either a standard (n = 14) or an enriched ONS (n = 14) using the Olink proteomics analysis pipeline (Olink® Target 96 Immuno-Oncology panel (Uppsala, Sweden))

Results

Patients receiving enriched ONS experienced an average weight gain of 1.4 kg and a muscle mass increase of 2.2 kg after 8 weeks, both statistically significant (p < 0.05), while no such improvements were observed in the standard ONS group. Inflammatory markers TRAIL and LAMP3 were significantly reduced, along with an increase in Gal-1, suggesting lower inflammation and enhanced myogenic differentiation. However, patients who failed to gain muscle mass with the enriched formula showed a more aggressive inflammatory profile, characterized by higher serum levels of soluble MUC16, ARG, and IL12RB1. Interestingly, muscle mass gain could be predicted before the intervention, as responders had lower baseline levels of PGF, CD28, and IL12RB1. These differences were specific to recipients of the enriched ONS, confirming its immunomodulatory effects.

Conclusions

Our findings support the use of enriched oral nutritional supplementation (ONS) as an effective strategy not only to enhance caloric and protein intake but also to promote anabolism and preserve muscle mass in cancer patients. The identification of immune profiles suggests that specific biomarkers could be used to predict which patients will benefit most from this type of intervention. This may allow for the implementation of personalized immunonutrition strategies that optimize resource allocation and improve clinical outcomes, particularly in vulnerable populations at risk of cachexia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsDietary SupplementsMuscle, SkeletalHumansMaleFemaleMiddle AgedAgedBiomarkersCachexiaWeight GainAdultImmunonutrition Diet

Stichwörter der Autor:innen

cancerimmunomodulationmuscle massoral nutritional supplementationprecision nutrition

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Mucosal Immunology Lab, Department of Paediatrics and Immunology, University of Valladolid, 47003 Valladolid, Spain.
  • Health Research Institute of Valladolid (IBioVALL), 47010 Valladolid, Spain.
  • Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.
  • Centro de Investigación de Endocrinología y Nutrición, Facultad de medicina, Universidad de Valladolid, 47003 Valladolid, Spain.
  • Servicio de Endocrinología y Nutrición, Hospital Virgen del Rocio, 41013 Sevilla, Spain.
  • Nutrimed Clinical Nutrition Medical Department, 35002 Las Palmas de Gran Canaria, Spain.

ORCID-Profile: Sara Cuesta-Sancho, Juan José López Gomez, Pedro Pablo García-Luna, Antonio J Martínez-Ortega, David Bernardo, Daniel de Luis

Förderung

  • Adventia Healthcare SL
  • Nutrimed Clinical Nutrition

Zitieren

APA

Cuesta-Sancho, S., Gomez, J. J. L., García-Luna, P. P., Primo, D., Martínez-Ortega, A. J., Izaola, O., Casañas, T., Calleja, A., Bernardo, D., & de Luis, D. (2025). Soluble Oncoimmunome Signatures Predict Muscle Mass Response to Enriched Immunonutrition in Cancer Patients: Subanalysis of a Multicenter Randomized Clinical Trial. Nutrients. https://doi.org/10.3390/nu17152421

Vancouver

Cuesta-Sancho S, Gomez JJL, García-Luna PP, Primo D, Martínez-Ortega AJ, Izaola O, et al. Soluble Oncoimmunome Signatures Predict Muscle Mass Response to Enriched Immunonutrition in Cancer Patients: Subanalysis of a Multicenter Randomized Clinical Trial. Nutrients. 2025. doi:10.3390/nu17152421

BibTeX
@article{CuestaSancho2025,
  author = {Cuesta-Sancho, Sara and Gomez, Juan José López and García-Luna, Pedro Pablo and Primo, David and Martínez-Ortega, Antonio J and Izaola, Olatz and Casañas, Tamara and Calleja, Alicia and Bernardo, David and de Luis, Daniel},
  title = {Soluble Oncoimmunome Signatures Predict Muscle Mass Response to Enriched Immunonutrition in Cancer Patients: Subanalysis of a Multicenter Randomized Clinical Trial},
  journal = {Nutrients},
  year = {2025},
  doi = {10.3390/nu17152421}
}
Kostenlos starten →